Publications septembre2022-janvier2023

Adénomes

Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study. Ilie MD, Villa C, Cuny T, Cortet C, Assié G, Baussart B, Cancel M, Chanson P, Decoudier B, Deluche E, Di Stefano AL, Drui D, Gaillard S, Goichot B, Huillard O, Joncour A, Larrieu-Ciron D, Libe R, Nars G, Vasiljevic A, Raverot G.Eur J Endocrinol. 2022 Sep 1:EJE-22-0647. doi: 10.1530/EJE-22-0647.

Clinical Biology of the Pituitary Adenoma. Melmed S, Kaiser UB, Lopes MB, Bertherat J, Syro LV, Raverot G, Reincke M, Johannsson G, Beckers A, Fleseriu M, Giustina A, Wass JAH, Ho KKY. Endocr Rev. 2022 Nov 25;43(6):1003-1037. doi: 10.1210/endrev/bnac010.PMID: 35395078

Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients. Burman P, Trouillas J, Losa M, McCormack A, Petersenn S, Popovic V, Theodoropoulou M, Raverot G, Dekkers OM; ESE survey collaborators †.Eur J Endocrinol. 2022 Sep 19;187(4):593-605. doi: 10.1530/EJE-22-0440. Print 2022 Oct 1.PMID: 36018781

Treatments of psychiatric disorders, hyperprolactinemia and dopamine agonists. Chanson P.Best Pract Res Clin Endocrinol Metab. 2022 Dec;36(6):101711.doi:10.1016/ j.beem. 2022.101711.

Immunotherapy in pituitary carcinomas and aggressive pituitary tumors. Raverot G, Ilie MD. Best Pract Res Clin Endocrinol Metab. 2022 Dec;36(6):101712. doi: 10.1016/j.beem.2022.101712. Epub 2022 Oct 12.PMID: 36274025 Review.

Biological and Therapeutic Implications of the Tumor Microenvironment in Pituitary AdenomasIlie MD, Vasiljevic A, Bertolino P, Raverot G. Endocr Rev. 2022 Oct 21:bnac024. doi: 10.1210/endrev/bnac024. Online ahead of print.PMID: 36269838

Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients Burman P, Trouillas J, Losa M, McCormack A, Petersenn S, Popovic V, Theodoropoulou M, Raverot G, Dekkers OM; ESE survey collaborators †. Eur J Endocrinol. 2022 Sep 19;187(4):593-605. doi: 10.1530/EJE-22-0440. Print 2022 Oct 1.PMID: 36018781

Starting point for benchmarking outcomes and reporting of pituitary adenoma surgery within the European Reference Network on Rare Endocrine Conditions (Endo-ERN): results from a meta-analysis and survey study. Zamanipoor Najafabadi AH, van der Meulen M, Priego Zurita AL, Faisal Ahmed S, van Furth WR, Charmandari E, Hiort O, Pereira AM, Dattani M, Vitali D, de Graaf JP, Biermasz NR; MTG6 Pituitary of Endo-ERN.Endocr Connect. 2022 Dec 13;12(1):e220349. doi: 10.1530/EC-22-0349. Print 2023 Jan 1.PMID: 36327151

Acromégalie

Preoperative Medical Treatment for Patients With Acromegaly: Yes or No? Albarel F, Cuny T, Graillon T, Dufour H, Brue T, Castinetti F.J Endocr Soc. 2022 Aug 4;6(9):bvac114. doi:10.1210/jendso/bvac114. eCollection 2022 Sep 1.PMID: 35965944.

Predictive factors of somatostatin receptor ligand response in acromegaly - a prospective study. Ilie MD, Tabarin A, Vasiljevic A, Bonneville JF, Moreau-Grangé L, Schillo F, Delemer B, Barlier A, Figarella-Branger D, Bisot-Locard S, Santos A, Chanson P, Raverot G. J Clin Endocrinol Metab. 2022 Sep 22:dgac512. doi: 10.1210/clinem/dgac512.

Impairment in **insulin** secretion without changes in **insulin** resistance explains hyperglycemia in patients with acromegaly treated with pasireotide LAR. Wolf P, Dormoy A, Maione L, Salenave S, Young J, Kamenický P, Chanson P.Endocr Connect. 2022 Nov 17;11(12):e220296. doi: 10.1530/EC-22-0296. Print 2022 Dec 1.

Second line treatment of acromegaly: Pasireotide or Pegvisomant?
Chiloiro S, Bianchi A, Giampietro A, Pontecorvi A, Raverot G, Marinis L.Best Pract Res Clin Endocrinol Metab. 2022 Dec;36(6):101684. doi: 10.1016/j.beem.2022.101684. Epub 2022 Jul 16.PMID: 35931640 Review.

Cushing

Long-term efficacy and safety of osilodrostat in Cushing's disease: final results from a Phase II study with an optional extension phase (LINC 2). Fleseriu M, Biller BMK, Bertherat J, Young J, Hatipoglu B, Arnaldi G, O'Connell P, Izquierdo M, Pedroncelli AM, Pivonello R. Pituitary. 2022 Dec;25(6):959-970. doi: 10.1007/s11102-022-01280-6. Epub 2022 Oct 11.

Efficacy and safety of osilodrostat in paraneoplastic Cushing's syndrome: a real-world multicenter study in France. Dormoy A, Haissaguerre M, Vitellius G, Cao CD, Geslot A, Drui D, Lasolle H, Vieira-Pinto O, Salenave S, François M, Puerto M, Boullay HD, Mayer A, Rod A, Laurent C, Chanson P, Reznik Y, Castinetti F, Chabre O, Baudin E, Raverot G, Tabarin A, Young J. J Clin Endocrinol Metab. 2022 Dec 6:dgac691. doi: 10.1210/clinem/dgac691. Online ahead of print.PMID: 36470583

Levoketoconazole in the treatment of patients with endogenous Cushing's syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS). Pivonello R, Zacharieva S, Elenkova A, Tóth M, Shimon I, Stigliano A, Badiu C, Brue T, Georgescu CE, Tsagarakis S, Cohen F, Fleseriu M. Pituitary. 2022 Dec;25(6):911-926. doi: 10.1007/s11102-022-01263-7. Epub 2022 Sep 9.PMID: 36085339

Cushing's disease: role of preoperative and primary medical therapy. Castinetti F. Pituitary. 2022 Oct;25(5):737-739. doi: 10.1007/s11102-022-01244-w. Epub 2022 Jul 2. PMID: 35780261 Review.

Is Desmopressin Useful in the Evaluation of Cushing Syndrome? Castinetti F, Lacroix A.J Clin Endocrinol Metab. 2022 Nov 23;107(11):e4295-e4301. doi: 10.1210/clinem/dgac533. PMID: 36103267 Review.

Medical management of Cushing's disease: When and how? Castinetti F.J Neuroendocrinol. 2022 Aug;34(8):e13120. doi: 10.1111/jne.13120. Epub 2022 Mar 29.PMID: 35348261 Review.

How best to monitor the specific side effects of medical treatments of Cushing's disease. Castinetti F.Best Pract Res Clin Endocrinol Metab. 2022 Dec;36(6):101718. doi: 10.1016/j.beem.022.101718. Epub 2022 Nov 14.

Chirurgie:

Corticotroph tumor progression after bilateral adrenalectomy: data from ERCUSYN.
Valassi E, Castinetti F, Ferriere A, Tsagarakis S, Feelders RA, Netea-Maier RT, Droste M, Strasburger CJ, Maiter D, Kastelan D, Chanson P, Webb SM, Demtröder F, Pirags V, Chabre O, Franz H, Santos A, Reincke M.Endocr Relat Cancer. 2022 Nov 2;29(12):681-691. doi: 10.1530/ERC-22-0074. Print 2022 Dec 1.PMID: 36197784

Déficits hypophysaires

Heterozygous variants in SIX3 and POU1F1 cause pituitary hormone deficiency in mouse and man. Bando H, Brinkmeier ML, Castinetti F, Fang Q, Lee MS, Saveanu A, Albarel F, Dupuis C, Brue T, Camper SA.Hum Mol Genet. 2023 Jan 13;32(3):367-385. doi: 10.1093/hmg/ddac192.PMID: 35951005

IGSF1 mutations are the most frequent genetic aetiology of thyrotropin deficiency.
Fourneaux R, Reynaud R, Mougel G, Castets S, Bretones P, Dauriat B, Edouard T, Raverot G, Barlier A, Brue T, Castinetti F, Saveanu A.Eur J Endocrinol. 2022 Nov 3;187(6):787-795. doi: 10.1530/EJE-22-0520. Print 2022 Dec 1.PMID: 36201163

A novel *TBX19* gene mutation in patients with isolated ACTH deficiency from distinct families with a common geographical origin.
Charnay T, Mougel G, Amouroux C, Gueorguieva I, Joubert F, Pertuit M, Reynaud R, Barlier A, Brue T, Saveanu A.Front Endocrinol (Lausanne). 2023 Feb 15;13:1080649. doi: 10.3389/fendo.2022.1080649. eCollection 2022.

Autres

The Challenging Management of Craniopharyngiomas in Adults: Time for a Reappraisal?
Cuny T, Buchfelder M, Dufour H, Grossman A, Gatta-Cherifi B, Jouanneau E, Raverot G, Vasiljevic A, Castinetti F. Cancers (Basel). 2022 Aug 7;14(15):3831. doi: 10.3390/cancers14153831.PMID:35954494.

Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Husebye ES, Castinetti F, Criseno S, Curigliano G, Decallonne B, Fleseriu M, Higham CE, Lupi I, Paschou SA, Toth M, van der Kooij M, Dekkers OM.Eur J Endocrinol. 2022 Oct 25;187(6):G1-G21. doi: 10.1530/EJE-22-0689. Print 2022 Dec 1.